Role of gemifloxacin in the management of community-acquired lower respiratory tract infections

International Journal of Antimicrobial Agents

Volumn 31, Issue 4, 2008, Pages 299-306

  Blondeau, Joseph M ^a,b   Tillotson, Glenn ^c  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Replidyne Inc   (United States)

Author keywords

Antimicrobial resistance; Community respiratory tract infections; Gemifloxacin; Health economics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIGOXIN; DRUG METABOLITE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; N ACETYL GEMIFLOXACIN; ORAL CONTRACEPTIVE AGENT; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; THEOPHYLLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; CHLAMYDOPHILA; CHRONIC BRONCHITIS; CHRONIC LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; CROSS ALLERGY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG ACTIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; LEGIONELLA; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; MACULOPAPULAR RASH; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA; NAUSEA; NECROSIS; NONHUMAN; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; RASH; SHORT SURVEY; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULITIS; VERTIGO; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; NAPHTHYRIDINES; RESPIRATORY TRACT INFECTIONS;

EID: 40849146982     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.12.003     Document Type: Short Survey

References (34)

1. O'Donnell D.E., Aron S., Bourbeau J., Hernandez P., Marciniuk D.D., Balter M., et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 14 Suppl. B (2007) 5B-32B
2. Miniño A.M., Arias E., Kochanek K.D., Murphy S.L., and Smith B.L. Deaths: final data for 2000. Natl Vital Stat Rep 50 (2002) 1-119
3. Ball P. Quinolone generations: natural history or natural selection?. J Antimicrob Chemother 46 Suppl. T1 (2000) 17-24
4. Domagala J. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33 (1994) 685-706
5. Pletz M.W.R., McGee L., Jorgenson J., Beall B., Facklam R.R., Whitney C.G., et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 48 (2004) 3491-3497
6. Blondeau J.M., and Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 5 (2004) 1117-1152
7. File Jr. T.M., and Iannini P.B. A profile of gemifloxacin, a new respiratory fluoroquinolone. Todays Ther Trends 21 (2003) 415-435
8. Lim S., Bast D., McGeer A., de Azavedo J., and Low D.E. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 9 (2003) 833-837
9. Heaton V.J., Ambler J., and Fisher L.M. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 44 (2000) 3112-3117
10. Hooper D.C. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 2 (1999) 38-55
11. Fisher L.M., Gould K.A., Pan X.-S., Patel S., and Heaton V.J. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. J Antimicrob Chemother 52 (2003) 312-316
12. Gillespie S.H., Voelker L.L., and Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist 8 (2002) 79-84
13. Chen D.K., McGeer A., De Azavedo J., Low D.E., and The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 341 (1999) 233-239
14. Perez-Trallero E., Garcia-Rey C., Martin-Sanchez A.M., Aguilar L., Garcia-de-Lomas J., Ruiz J., et al. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 46 (2002) 2665-2667
15. Berry V., Page R., Satterfield J., Singley C., Straub R., and Woodnutt G. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. J Antimicrob Chemother 45 Suppl. S1 (2000) 79-85
16. Berry V., Page R., Satterfield J., Singley C., Straub R., and Woodnutt G. Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection. J Antimicrob Chemother 45 Suppl. S1 (2000) 87-93
17. Bast D., Dresser L., Duncan C.L., Walker S., Mandell L.A., Low D.E., et al. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice. J Chemother 18 (2006) 45-51
18. Oscient Pharmaceuticals. Gemifloxacin (FACTIVE) prescribing information (2007), Oscient Pharmaceuticals, Waltham, MA
19. Seo S.M., Lee S.H., Choi Y.J., Jeong Y.N., Lee S.H., Kim I.C., et al. Pharmacokinetics of LB20304, a new fluoroquinolone in rats and dogs. Arch Pharmacol Res 19 (1996) 359-367
20. Gee T., Andrews J.M., Ashby J.P., Marshall G., and Wise R. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J Antimicrob Chemother 47 (2001) 431-434
21. Olofsson S.K., Marcusson L.L., Komp Lindgren P., Hughes D., and Cars O. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57 (2006) 1116-1121
22. Mandell L.A., Bartlett J.G., Dowell S.F., File Jr. T.M., and Musher D.M. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37 (2003) 1405-1433
23. Ball P., File Jr. T.M., Twynholm M., Henkel T., and 061 Study Group. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 18 (2001) 19-27
24. Lode H., File Jr. T.M., Mandell L.A., Ball P., Pypstra R., Thomas M., et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 24 (2002) 1915-1936
25. File Jr. T.M., Schlemmer B., Garau J., Cupo M., Young C., and 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 48 (2001) 67-74
26. Leophonte P., File Jr. T.M., and Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 98 (2004) 708-720
27. Oscient Pharmaceuticals. Gemifloxacin (FACTIVE) prescribing information (2004), Oscient Pharmaceuticals, Waltham, MA
28. Wilson R., Schentag J.J., Ball P., Mandell L.A., and 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 24 (2002) 639-652
29. Sethi S., Fogarty C., and Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med 98 (2004) 697-707
30. File Jr. T.M., Sclemmer B., Garau J., Lode H., Lynch S., Young C., et al. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. J Chemother 12 (2000) 314-325
31. Ball P., Wilson R., Mandell L.A., Brown J., Henkel T., and 069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J Chemother 13 (2001) 288-298
32. Wilson R., Langan C., Ball P., Bateman K., Pypstra R., and Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 97 (2003) 242-249
33. Halpern M.T., Palmer C.S., Zodet M., and Kirsch J. Cost-effectiveness of gemifloxacin: results from the GLOBE Study. Am J Health Syst Pharm 59 (2002) 1357-1365
34. Bhavnani S.M., and Ambrose P.G. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis (2007) [Epub ahead of print]